MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma

scientific article published on 01 January 2019

MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.7150/THNO.27576
P932PMC publication ID6376176
P698PubMed publication ID30809285

P50authorPierfranco ConteQ56798835
Giulia GrisendiQ57012601
Giulia OrsiQ87771986
Giulia GolinelliQ87920946
Giulia RovestiQ89326396
P2093author name stringAlessandra Recchia
Marco Bestagno
Edwin M Horwitz
Elena Veronesi
Massimo Dominici
Filippo Rossignoli
Olivia Candini
Tiziana Petrachi
Francesca Miselli
Carlotta Spano
Benedetta Petocchi
Elisabetta Manuela Foppiani
Gregorio Medici
Ilenia Mastrolia
Massimo Pinelli
P2860cites workOnto better TRAILs for cancer treatmentQ26768160
Microtubule-binding agents: a dynamic field of cancer therapeuticsQ27690249
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsQ28391040
c-FLIP, a master anti-apoptotic regulatorQ28391119
Albumin-bound paclitaxel: a next-generation taxaneQ29027108
Cancer statistics, 2016Q29547383
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Q29615661
TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivoQ30318545
Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo.Q33483354
Advances in mesenchymal stem cell-mediated gene therapy for cancer.Q34135233
Gene therapy in pancreatic cancerQ34302954
Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinomaQ34458449
Overcoming drug resistance in pancreatic cancer.Q35036615
Gene and cell therapy for pancreatic cancerQ35541787
Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.Q36561621
Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effectsQ37073589
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapyQ37140126
The TRAIL apoptotic pathway in cancer onset, progression and therapyQ37278043
Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer modelQ37310677
In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies.Q37621597
nab-Paclitaxel mechanisms of action and deliveryQ38114701
Pancreatic cancer: a comprehensive review and updateQ38158783
Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cellsQ38308753
Pancreatic cancer: from state-of-the-art treatments to promising novel therapiesQ38396634
Changing the course of pancreatic cancer--Focus on recent translational advancesQ38753998
Embelin prevents LMP1-induced TRAIL resistance via inhibition of XIAP in nasopharyngeal carcinoma cellsQ38763961
Tumor Stroma Manipulation By MSC.Q38764997
Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells.Q38785499
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisQ38829982
Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancerQ38840234
Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancerQ38850605
Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cellsQ38918317
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomasQ38938230
Surrounding pancreatic adenocarcinoma by killer mesenchymal stromal/stem cells.Q38993056
Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in miceQ39028542
Adipose tissue-derived stromal cells primed in vitro with paclitaxel acquire anti-tumor activityQ39094393
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cellsQ39319003
Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cellsQ39649739
Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosisQ39653516
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cellsQ39765503
Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer.Q39852557
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathwayQ41205677
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.Q41501622
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapyQ43100976
TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cellsQ44226747
The future of mesenchymal stem cell-based therapeutic approaches for cancer - From cells to ghostsQ45875024
Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cellsQ57243535
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic CancerQ61797115
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor ELQ71046859
Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin CQ73895525
Pancreatic cancerQ87198210
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectpaclitaxelQ423762
pancreatic adenocarcinomaQ18556189
P304page(s)436-448
P577publication date2019-01-01
P1433published inTheranosticsQ21051383
P1476titleMSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma
P478volume9